Pavel Jindra

Mar 12, 2024 | nature.com | Pavel Jindra

To the Editor:Tyrosine kinase inhibitor (TKI) therapy discontinuation with the aim of achieving treatment-free remission (TFR) is becoming more frequent, as an increasing number of chronic myeloid leukemia (CML) patients are achieving stable deep molecular response (DMR; i.e. BCR::ABL1 transcript level ≤0.01% on the International Scale); however, many challenges remain unresolved [1].

Mar 28, 2023 | nature.com | Olivier Tournilhac |Peter Dreger |Vladan Vucinic |Pavel Jindra |Patrice Chevallier |Edouard Forcade | +6 more

AbstractAllogeneic transplantation (allo-HCT) is a curative treatment in CLL whose efficacy including the most severe forms had led to the 2006 EBMT recommendations. The advent after 2014 of targeted therapies has revolutionized CLL management, allowing prolonged control to patients who have failed immunochemotherapy and/or have TP53 alterations. We analysed the pre COVID pandemic 2009–2019 EBMT registry.